Is PPAR𝛾 a Prospective Player in HIV-1-Associated Bone Disease?
Currently infection with the human immunodeficiency virus-1 (HIV-1) is in most instances a chronic disease that can be controlled by effective antiretroviral therapy (ART). However, chronic use of ART has been associated with a number of toxicities; including significant reductions in bone mineral d...
Saved in:
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2009-01-01
|
Series: | PPAR Research |
Online Access: | http://dx.doi.org/10.1155/2009/421376 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832568045673906176 |
---|---|
author | Eoin J. Cotter Patrick W. Mallon Peter P. Doran |
author_facet | Eoin J. Cotter Patrick W. Mallon Peter P. Doran |
author_sort | Eoin J. Cotter |
collection | DOAJ |
description | Currently infection with the human immunodeficiency virus-1 (HIV-1) is in most instances a chronic disease that can be controlled by effective antiretroviral therapy (ART). However, chronic use of ART has been associated with a number of toxicities; including significant reductions in bone mineral density (BMD) and disorders of the fat metabolism. The peroxisome proliferator-activated receptor gamma (PPAR𝛾) transcription factor is vital for the development and maintenance of mature and developing adipocytes. Alterations in PPAR𝛾 expression have been implicated as a factor in the mechanism of HIV-1-associated lipodystrophy. Both reduced BMD and lipodystrophy have been well described as complications of HIV-1 infection and treatment, and a question remains as to their interdependence. Interestingly, both adipocytes and osteoblasts are derived from a common precursor cell type; the mesenchymal stem cell. The possibility that dysregulation of PPAR𝛾 (and the subsequent effect on both osteoblastogenesis and adipogenesis) is a contributory factor in the lipid- and bone-abnormalities observed in HIV-1 infection and treatment has also been investigated. This review deals with the hypothesis that dysregulation of PPAR𝛾 may underpin the bone abnormalities associated with HIV-1 infection, and treats the current knowledge and prospective developments, in our understanding of PPAR𝛾 involvement in HIV-1-associated bone disease. |
format | Article |
id | doaj-art-f1473203346c4310b905172e39bce2dc |
institution | Kabale University |
issn | 1687-4757 1687-4765 |
language | English |
publishDate | 2009-01-01 |
publisher | Wiley |
record_format | Article |
series | PPAR Research |
spelling | doaj-art-f1473203346c4310b905172e39bce2dc2025-02-03T01:00:00ZengWileyPPAR Research1687-47571687-47652009-01-01200910.1155/2009/421376421376Is PPAR𝛾 a Prospective Player in HIV-1-Associated Bone Disease?Eoin J. Cotter0Patrick W. Mallon1Peter P. Doran2Clinical Research Center, University College Dublin, Belfield, 4 Dublin, IrelandSchool of Medicine & Medical Science, University College Dublin, Belfield, 4 Dublin, IrelandClinical Research Center, University College Dublin, Belfield, 4 Dublin, IrelandCurrently infection with the human immunodeficiency virus-1 (HIV-1) is in most instances a chronic disease that can be controlled by effective antiretroviral therapy (ART). However, chronic use of ART has been associated with a number of toxicities; including significant reductions in bone mineral density (BMD) and disorders of the fat metabolism. The peroxisome proliferator-activated receptor gamma (PPAR𝛾) transcription factor is vital for the development and maintenance of mature and developing adipocytes. Alterations in PPAR𝛾 expression have been implicated as a factor in the mechanism of HIV-1-associated lipodystrophy. Both reduced BMD and lipodystrophy have been well described as complications of HIV-1 infection and treatment, and a question remains as to their interdependence. Interestingly, both adipocytes and osteoblasts are derived from a common precursor cell type; the mesenchymal stem cell. The possibility that dysregulation of PPAR𝛾 (and the subsequent effect on both osteoblastogenesis and adipogenesis) is a contributory factor in the lipid- and bone-abnormalities observed in HIV-1 infection and treatment has also been investigated. This review deals with the hypothesis that dysregulation of PPAR𝛾 may underpin the bone abnormalities associated with HIV-1 infection, and treats the current knowledge and prospective developments, in our understanding of PPAR𝛾 involvement in HIV-1-associated bone disease.http://dx.doi.org/10.1155/2009/421376 |
spellingShingle | Eoin J. Cotter Patrick W. Mallon Peter P. Doran Is PPAR𝛾 a Prospective Player in HIV-1-Associated Bone Disease? PPAR Research |
title | Is PPAR𝛾 a Prospective Player in HIV-1-Associated Bone Disease? |
title_full | Is PPAR𝛾 a Prospective Player in HIV-1-Associated Bone Disease? |
title_fullStr | Is PPAR𝛾 a Prospective Player in HIV-1-Associated Bone Disease? |
title_full_unstemmed | Is PPAR𝛾 a Prospective Player in HIV-1-Associated Bone Disease? |
title_short | Is PPAR𝛾 a Prospective Player in HIV-1-Associated Bone Disease? |
title_sort | is ppar𝛾 a prospective player in hiv 1 associated bone disease |
url | http://dx.doi.org/10.1155/2009/421376 |
work_keys_str_mv | AT eoinjcotter ispparγaprospectiveplayerinhiv1associatedbonedisease AT patrickwmallon ispparγaprospectiveplayerinhiv1associatedbonedisease AT peterpdoran ispparγaprospectiveplayerinhiv1associatedbonedisease |